Madrigal Pharmaceuticals (MDGL) PT Raised to $193 at Canaccord Genuity, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $400.43 +1.04%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Canaccord Genuity analyst Edward Nash raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $193.00 (from $179.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Madrigal Pharmaceuticals (MDGL) PT Raised to $743 at Truist Securities
- Pfizer (PFE) PT Raised to $40 at Argus
- Kotak Upgrades Niva Bupa Health Insurance (NIVABUPA:IN) to Buy (1)
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Earnings, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
